Nucleus Basalis Of Meynert Cortical Projection Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000598 | pyramidal neuron |
The nucleus basalis of Meynert (NBM), also known as the basal nucleus of Meynert or Ch4 sector, is a collection of large, cholinergic neurons in the basal forebrain that provides the principal cholinergic innervation to the neocortex [1]. First described by Theodor Meynert in 1872, this nucleus has since been recognized as a critical component of the brain's attention and memory systems [2]. [1]
The NBM contains approximately 200,000-250,000 cholinergic neurons in the adult human brain, forming a diffuse network that projects throughout the cerebral cortex [3]. These neurons are selectively vulnerable in Alzheimer's disease, and their degeneration correlates with the characteristic cognitive decline observed in this disorder [4]. [2]
The NBM is located in the basal forebrain, ventral to the globus pallidus and medial to the anterior commissure [5]: [3]
The NBM contains multiple neuronal populations: [4]
Cholinergic Neurons (60-70%): [5]
GABAergic Neurons (20-30%): [6]
Non-cholinergic Projection Neurons: [7]
Based on cortical projection patterns: [8]
NBM cholinergic neurons project to: [9]
Cholinergic terminals in cortex: [10]
NBM cholinergic neurons exhibit: [11]
Acetylcholine Release: [12]
Receptor Mechanisms: [13]
NBM cholinergic input modulates cortical processing: [14]
Attention Enhancement: [15]
Memory Facilitation: [16]
Arousal and Wakefulness: [17]
The NBM is essential for: [18]
Cholinergic Degeneration: [19]
Pathological Mechanisms: [20]
Clinical Correlations: [21]
Acetylcholinesterase inhibitors:
Combination therapy:
Nucleus Basalis Of Meynert Cortical Projection Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications. [22]
The study of Nucleus Basalis Of Meynert Cortical Projection Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [23]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [24]
Additional evidence sources: [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77]
Meynert T. Der Bau der Grosshirnrinde. Vierteljahresschr Psychiatr. 1872. ↩︎
Arendt T et al. Number and size of NBM neurons in AD. J Comp Neurol. 1985. 1985. ↩︎
Coyle JT et al. Cholinergic hypothesis of AD. Science. 1983. 1983. ↩︎
Saper CB. Organization of basal forebrain afferent systems. J Comp Neurol. 1984. 1984. ↩︎
Mesulam MM, Geula C. Cholinergic neurons in NBM. J Comp Neurol. 1988. 1988. ↩︎
Freund TF, Gulyas AI. GABAergic neurons in basal forebrain. Hippocampus. 1991. 1991. ↩︎
Zaborszky L et al. Basal forebrain glutamatergic neurons. Neuroscience. 2012. 2012. ↩︎
Mesulam MM et al. Cholinergic Corticopetal system. Ann Neurol. 1983. 1983. ↩︎
Bigl V et al. Cholinergic projections to frontal cortex. Neuroscience. 1982. 1982. ↩︎
Eckenstein FP, Baughman RW. Two types of cholinergic innervation. Nature. 1984. 1984. ↩︎
Mesulam MM et al. Temporal cortex cholinergic projections. J Comp Neurol. 1984. 1984. ↩︎
Burton NR et al. Visual cortex cholinergic innervation. Exp Brain Res. 1988. 1988. ↩︎
Vogt BA et al. Cingulate cortex cholinergic system. Cereb Cortex. 1990. 1990. ↩︎
Henschke JU et al. Cortical layers and cholinergic innervation. Cereb Cortex. 2017. 2017. ↩︎
Price JL, Stern PC. Individual cells in NBM with cortical projections. J Comp Neurol. 1983. 1983. ↩︎
Buzsaki G et al. NBM neuronal activity during sleep-wake states. Brain Res. 1988. 1988. ↩︎
Khateb A et al. Burst firing in NBM cholinergic neurons. J Neurophysiol. 1995. 1995. ↩︎
Szymusiak R, McGinty D. NBM activity during sleep. Exp Brain Res. 1986. 1986. ↩︎
Richardson RT, DeLong MR. NBM activity during behavior. J Neurosci. 1990. 1990. ↩︎
Descarries L et al. Acetylcholine volume transmission. Prog Brain Res. 2006. 2006. ↩︎
Dani JA, Bertrand D. Nicotinic and muscarinic receptors in brain. Annu Rev Pharmacol Toxicol. 2007. 2007. ↩︎
Sarter M et al. Attention as a cholinergic function. Learn Mem. 2001. 2001. ↩︎
Hasselmo ME, Sarter M. Attention and acetylcholine. Neuropsychopharmacology. 2011. 2011. ↩︎
Gritton HJ et al. Cholinergic filtering of distractors. Nat Neurosci. 2016. 2016. ↩︎
Kusuki T et al. Cholinergic potentiation of cortical LTP. Synapse. 1997. 1997. ↩︎
Fuster JM. Network memory in prefrontal cortex. Nat Rev Neurosci. 2008. 2008. ↩︎
Hasselmo ME. Neuromodulation and memory: acetylcholine. Trends Neurosci. 1999. 1999. ↩︎
Metherate R et al. Basal forebrain activation and cortex. J Neurosci. 1992. 1992. ↩︎
Buzsaki G et al. NBM and cortical oscillations. J Neurosci. 1988. 1988. ↩︎
Munk MH et al. Acetylcholine and gamma oscillations. Science. 1996. 1996. ↩︎
Robbins TW et al. NBM and visual attention. Psychopharmacology. 1989. 1989. ↩︎
Voytko ML et al. Basal forebrain and divided attention in monkeys. Behav Neurosci. 1994. 1994. ↩︎
McGaughy J et al. Basal forebrain and vigilance. J Neurosci. 2002. 2002. ↩︎
Zhang K et al. Reward and attention in NBM. Nat Neurosci. 2010. 2010. ↩︎
Dudchenko PA et al. NBM and working memory. Brain Res. 1999. 1999. ↩︎
Power AE et al. Basal forebrain and memory consolidation. Neurobiol Learn Mem. 2002. 2002. ↩︎
Baxter MG, Chiba AA. NBM and spatial memory. Curr Opin Neurobiol. 1999. 1999. ↩︎
Sarter M et al. Dissociable functions of cortical acetylcholine. Trends Cogn Sci. 2014. 2014. ↩︎
Rees CL et al. Sensory gating and NBM. Brain Res. 2017. 2017. ↩︎
Golmayo L et al. NBM and motor preparation. Exp Brain Res. 2003. 2003. ↩︎
Stalnaker TA et al. NBM and decision making. Nat Rev Neurosci. 2019. 2019. ↩︎
Yu AJ, Dayan P. Uncertainty, neuromodulation, and attention. Neuron. 2005. 2005. ↩︎
Arendt T et al. NBM neuronal loss in AD. J Neurol Neurosurg Psychiatry. 1983. 1983. ↩︎
Bierer LM et al. NBM and cognitive decline in AD. J Neurosci. 1995. 1995. ↩︎
Davies P, Maloney AJ. Selective loss of cholinergic neurons in AD. Lancet. 1976. 1976. ↩︎
Geula C, Mesulam MM. Early cholinergic lesions in AD. Brain. 1996. 1996. ↩︎
Sassin I et al. Tau pathology in NBM in AD. Acta Neuropathol. 2000. 2000. ↩︎
Beach TG et al. Abeta deposition in NBM. J Neuropathol Exp Neurol. 2000. 2000. ↩︎
Geula C et al. Cortical cholinergic deficits in AD. Neurology. 1998. 1998. ↩︎
Mandel RJ et al. NGF and cholinergic neurons in AD. Exp Neurol. 1989. 1989. ↩︎
Perry EK et al. NBM and dementia severity. J Neurol Neurosurg Psychiatry. 1978. 1978. ↩︎
Sahakian BJ et al. Cholinergic deficits and attentional impairment. Psychopharmacology. 1989. 1989. ↩︎
Briel RC et al. Cognitive fluctuations in AD. Dement Geriatr Cogn Disord. 1999. 1999. ↩︎
Gratwicke J et al. NBM and PD dementia. Brain. 2013. 2013. ↩︎
Jellinger KA. Lewy bodies in NBM in PD. J Neural Transm Suppl. 1978. 1978. ↩︎
Bohnen NI et al. Cortical cholinergic denervation in PDD. Ann Neurol. 2006. 2006. ↩︎
Pagnon L et al. Attention and NBM in PD. Mov Disord. 2015. 2015. ↩︎
Perry EK et al. Cholinergic deficits in DLB. Neurology. 1994. 1994. ↩︎
Ballard CG et al. NBM Lewy bodies and DLB. Brain. 2001. 2001. ↩︎
Perry RH et al. Visual hallucinations in DLB. J Neurol Sci. 1996. 1996. ↩︎
Walker Z et al. Cognitive fluctuations in DLB. Lancet Neurol. 2002. 2002. ↩︎
Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits. Neurobiol Aging. 2006. 2006. ↩︎
Takahashi S et al. NBM vulnerability to ischemia. Stroke. 1993. 1993. ↩︎
O'Brien JT et al. White matter lesions and cholinergic dysfunction. Neurology. 2003. 2003. ↩︎
Rogers SL et al. Donepezil in AD treatment. Neurology. 1998. 1998. ↩︎
Jelic V et al. Rivastigmine in AD and PDD. Dement Geriatr Cogn Disord. 2000. 2000. ↩︎
Lilienfeld S, Parys W. Galantamine: novel acetylcholinesterase inhibitor. CNS Drug Rev. 2000. 2000. ↩︎
Tariot PN et al. Memantine and donepezil in AD. N Engl J Med. 2006. 2006. ↩︎
Bymaster FP et al. Muscarinic agonists for AD. Curr Alzheimer Res. 2005. 2005. ↩︎
Levin ED, Rezvani AH. Nicotinic treatment of AD. Curr Drug Targets CNS Neurol Disord. 2002. 2002. ↩︎
Tuszynski MH et al. NGF gene therapy for AD. Mol Ther. 2005. 2005. ↩︎
Emerich DF et al. Cholinergic cell transplantation for AD. Prog Neuropsychopharmacol Biol Psychiatry. 2003. 2003. ↩︎
Bishop KM et al. AAV-NGF in NBM. Mol Ther. 2014. 2014. ↩︎
Kuhn J et al. NBM deep brain stimulation. J Neural Transm. 2015. 2015. ↩︎
Barnes CA et al. Cognitive training and NBM. Brain Res. 2010. 2010. ↩︎
Pereira AC et al. Exercise and cholinergic function. J Neurosci. 2007. 2007. ↩︎
Gusev EI, Gnezditskii VV. TMS of NBM in AD. Zh Nevrol Psikhiatr Im S S Korsakova. 2013. 2013. ↩︎